.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Queensland Health
Moodys
Farmers Insurance
Teva
Federal Trade Commission
Cipla
Cerilliant
Express Scripts

Generated: November 19, 2017

DrugPatentWatch Database Preview

Valeant Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT PHARMS LLC, and when can generic versions of VALEANT PHARMS LLC drugs launch?

VALEANT PHARMS LLC has seven approved drugs.

There are two US patents protecting VALEANT PHARMS LLC drugs.

There are three hundred and sixty-seven patent family members on VALEANT PHARMS LLC drugs in thirty-six countries and seventeen supplementary protection certificates in ten countries.

Summary for Valeant Pharms Llc

International Patents:367
US Patents:2
Tradenames:6
Ingredients:6
NDAs:7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-001Nov 4, 1993ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
CAPITAL AND CODEINE
acetaminophen; codeine phosphate
SUSPENSION;ORAL086024-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-002Jan 29, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-001Jan 29, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Llc
MESTINON
pyridostigmine bromide
TABLET, EXTENDED RELEASE;ORAL011665-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
MESTINON
pyridostigmine bromide
TABLET;ORAL009829-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
LIBRIUM
chlordiazepoxide hydrochloride
INJECTABLE;INJECTION012301-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-002Nov 4, 1993ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
LIBRIUM
chlordiazepoxide hydrochloride
INJECTABLE;INJECTION012301-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-002Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-002Nov 4, 1993► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-001Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-001Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-002Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Valeant Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,472,841 Methods for identifying nucleic acid ligands of human neutrophil elastase► Subscribe
7,153,948High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)► Subscribe
5,849,479 High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)► Subscribe
5,773,598 Systematic evolution of ligands by exponential enrichment: chimeric selex► Subscribe
7,005,260Tenascin-C nucleic acid ligands► Subscribe
5,670,637 Nucleic acid ligands► Subscribe
5,639,868 High-affinity RNA ligands for basic fibroblast growth factor► Subscribe
6,048,698 Parallel SELEX.TM.► Subscribe
6,582,918 Platelet derived growth factor (PDGF) nucleic acid ligand complexes► Subscribe
5,648,214 High-affinity oligonucleotide ligands to the tachykinin substance P► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Pharms Llc Drugs

Country Document Number Estimated Expiration
European Patent Office0832291► Subscribe
European Patent Office0533838► Subscribe
World Intellectual Property Organization (WIPO)0109159► Subscribe
JapanH09502354► Subscribe
Australia5301996► Subscribe
Japan2000508169► Subscribe
Spain2321243► Subscribe
Australia773815► Subscribe
Australia749273► Subscribe
World Intellectual Property Organization (WIPO)9507364► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/1997Austria► SubscribePRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827
2006 00021Denmark► Subscribe
/1999Austria► SubscribePRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0234Netherlands► Subscribe300234, 20171017, EXPIRES: 20210130
2006004,C0957929Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C/GB97/088United Kingdom► SubscribePRODUCT NAME: TOLCAPONE; REGISTERED: CH 54055/01 19970225; CH 54055/02 19970225; UK EU/1/97/044/001 19970827; UK EU/1/97/044/002 19970827; UK EU/1/97/044/003 19970827; UK EU/1/97/044/004 19970827; UK EU/1/97/044/005 19970827; UK EU/1/97/044/006 19970827
C0013Belgium► SubscribePRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
0957929/01Switzerland► SubscribePRODUCT NAME: PEGAPTANIB; REGISTRATION NUMBER/DATE: SWISSMEDIC 57459 15.02.2006
90041Netherlands► SubscribePRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
Colorcon
Chinese Patent Office
Covington
Chubb
Fish and Richardson
US Army
Argus Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot